Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Became director and Audit Committee Chair in April 2026. CFO of Syndax Pharmaceuticals since June 2022. Previously served as CFO of Optinose, Fibrocell Science, NuPathe, PuriCore, and Biosyn with experience in capital raising and infrastructure development.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

Syndax Pharmaceuticals Inc

Open Syndax Pharmaceuticals Inc profile →

Chief Financial Officer at Syndax Pharmaceuticals Inc

Start not stated → End not stated

current · source reported

Observed: 2026-09-27

Syndax Pharmaceuti…Syndax Pharmaceuticals IncKeith A. Goldan

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingSNDX DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 2 · Sec FilingABEO DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:keith-a-goldan
Record version
public-0

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. SNDX DEF 14A executive officers

    sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Syndax Pharmaceuticals Inc · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 5, 2026

  2. Open source

    sec def 14a · Source published: Apr 30, 2026 · Retrieved: Sep 13, 2026

    Supports 1 claim
    • Professional Role: Chief Financial Officer at Syndax Pharmaceuticals Inc · Claim reviewed: Sep 13, 2026

  3. ABEO DEF 14A executive officers

    sec filing · Source published: Apr 27, 2026 · Retrieved: May 15, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at ABEONA THERAPEUTICS INC. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Director and Chair of Audit Committee · Claim reviewed: May 15, 2026
    • Other Company Role: Keith A. Goldan is also linked to Syndax Pharmaceuticals, Inc. as Chief Financial Officer. · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at ABEONA THERAPEUTICS INC.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Syndax Pharmaceuticals Inc1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Director and Chair of Audit Committee1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Other Company Role · Source reportedKeith A. Goldan is also linked to Syndax Pharmaceuticals, Inc. as Chief Financial Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources3 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  2. https://www.sec.gov/Archives/edgar/data/1395937/000119312526197859/sndx-20260430.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 13, 2026

    Supports: Chief Financial Officer at Syndax Pharmaceuticals Inc (NASDAQ: SNDX)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background